About the Startup
German biotech company developing non-viral CAR-T cell therapies and platform technologies (including ex-vivo clinical programs and proprietary non-viral, potentially in-vivo CAR-T generation) to make CAR-T therapies more economical, scalable and accessible.
Frequently Asked Questions
What type of funding round did T-CURX GmbH raise?
T-CURX GmbH raised a series-a round.
How much did T-CURX GmbH raise in its series-a?
T-CURX GmbH raised $20,000,000 USD in its series-a.
When did T-CURX GmbH raise its series-a?
T-CURX GmbH raised its series-a on 2025-12-18.
Who invested in T-CURX GmbH's series-a?
The investors in T-CURX GmbH's series-a are: BiomedVC, HighLight Capital (HLC), i&iBio Fund, Existing and new private investors.
What type of investment was T-CURX GmbH's series-a?
T-CURX GmbH's series-a was a equity investment.